Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Abeona Therapeutics (ABEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 363,385
  • Shares Outstanding, K 47,940
  • Annual Sales, $ 840 K
  • Annual Income, $ -27,320 K
  • 36-Month Beta 1.81
  • Price/Sales 434.19
  • Price/Cash Flow N/A
  • Price/Book 2.64

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.42
  • Number of Estimates 3
  • High Estimate -0.31
  • Low Estimate -0.55
  • Prior Year -0.19
  • Growth Rate Est. (year over year) -121.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.25 +1.59%
on 11/20/18
9.55 -22.88%
on 12/10/18
-0.14 (-1.80%)
since 11/14/18
3-Month
6.94 +6.12%
on 11/14/18
14.32 -48.59%
on 09/17/18
-6.99 (-48.68%)
since 09/14/18
52-Week
6.94 +6.12%
on 11/14/18
22.00 -66.52%
on 04/23/18
-8.74 (-54.25%)
since 12/14/17

Most Recent Stories

More News
Abeona Therapeutics (ABEO) in Focus: Stock Moves 5.5% Higher

Abeona Therapeutics (ABEO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

ABEO : 7.36 (-2.84%)
ALXN : 109.43 (-2.67%)
Why Abeona Therapeutics (ABEO) Could Be Positioned for a Slump

Abeona Therapeutics (ABEO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

ANIK : 30.23 (-3.05%)
ABEO : 7.36 (-2.84%)
Abeona Therapeutics Details Pathway for Advancing Lead Clinical Programs and Unveils New Cystic Fibrosis Program Born from Next Generation AIM(TM) Vector Platform at 2018 R&D Day

EB-101 pivotal trial for Recessive Dystrophic Epidermolysis Bullosa planned for mid-2019 enrollment

ABEO : 7.36 (-2.84%)
Moving Average Crossover Alert: Abeona Therapeutics

Abeona Therapeutics Inc. (ABEO) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

ABEO : 7.36 (-2.84%)
Abeona Therapeutics to Host R&D Day on December 6, 2018

Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced...

ABEO : 7.36 (-2.84%)
Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Abeona Therapeutics Inc. (NASDAQ:ABEO),...

IMMY : 5.83 (-2.02%)
CYTK : 7.70 (-2.65%)
AUPH : 6.01 (-1.15%)
LNT : 45.32 (-1.73%)
GLDD : 7.31 (-2.27%)
ABEO : 7.36 (-2.84%)
Abeona Therapeutics Announces CEO Transition

Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced...

ABEO : 7.36 (-2.84%)
Abeona Therapeutics (ABEO) Reports Q3 Loss, Tops Revenue Estimates

Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of -47.83% and 68.04%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?...

ABEO : 7.36 (-2.84%)
Abeona Therapeutics: 3Q Earnings Snapshot

DALLAS (AP) _ Abeona Therapeutics Inc. (ABEO) on Friday reported a loss of $16.4 million in its third quarter.

ABEO : 7.36 (-2.84%)
Abeona Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights

Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced...

ABEO : 7.36 (-2.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ABEO with:

Business Summary

Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States.

See More

Key Turning Points

2nd Resistance Point 7.87
1st Resistance Point 7.62
Last Price 7.36
1st Support Level 7.21
2nd Support Level 7.05

See More

52-Week High 22.00
Fibonacci 61.8% 16.25
Fibonacci 50% 14.47
Fibonacci 38.2% 12.69
Last Price 7.36
52-Week Low 6.94

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar